ArticleJournal of the American Heart Association2025
Validation of the Hemodynamic Classification System for Hemodynamic-Related Events in Patients With Durable Left Ventricular Assist Devices.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDurable left ventricular assist device (dLVAD) physiology predisposes to right heart failure (RHF) and aortic insufficiency (AI), recently labeled hemodynamic-related events (HDREs). We sought to validate the recently proposed dLVAD Hemodynamic Classification System for HDREs.
methodsRHF and AI HDREs were adjudicated, staged, and phenotyped on the basis of the Hemodynamic Classification System assessed at 6 months after dLVAD implantation. The primary outcome was a composite of HF hospitalization or cardiovascular death between 6 and 24 months after dLVAD implantation.
resultsAmong 183 qualifying consecutive patients with 6-month assessments, RHF HDRE was adjudicated in all cases and AI HDRE in 161 (88.0%). Overall, 53 (29.0%) patients developed an RHF HDRE and 26 (16.0%) an AI HDRE (phenotypes: 39 isolated RHF, 15 isolated AI, 11 combined RHF-AI, 3 not adjudicated). At pre-dLVAD assessment, age and pulmonary artery pulsatility index were independently associated with RHF HDRE and pre-dLVAD AI and systolic pulmonary artery pressure with AI HDRE. RHF HDRE (adjusted hazard ratio [HR], 2.69 [95% CI, 1.14-6.34];
conclusionsWe validated the dLVAD Hemodynamic Classification System for HDREs as a valuable tool to identify pathophysiological and clinical clusters of patients, linking it with significant prognostic implications. Its adoption may pave the way for targeted strategies aimed at mitigating HDREs and enhancing the long-term success of dLVAD support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.